The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. This NICE guidance is based on evidence that regular systematic review of people with diabetes and achievement of glucose, blood pressure and cardiovascular risk standards maintains health and reduces long term complications.

This is an overview of the treatment and demographics of 227,435 adults with type 1 diabetes. From 2019 to 2022 glucose control in people with type 1 diabetes in England and Wales improved while blood pressure control deteriorated. Use of diabetes technology (wearable glucose monitoring devices in England and insulin pumps in England and Wales) was associated with lower glucose levels. Diabetes technology was used less by those in the most deprived groups and in ethnic minorities. 30% of people with type 1 diabetes did not attend specialist care in 2021-22 and were less likely to receive annual checks or achieve treatment targets as recommended by the National Institute for Health and Care Excellence (NICE).

North America Insulin Syringe Market size was valued at USD 259 Million in 2024 and is projected to reach USD 290 Million by 2032, growing at a CAGR of 1.7% from 2025 to 2032.

Key Market Drivers:

Increasing Diabetes Prevalence: According to the Centers for Disease Control and Prevention's (CDC) 2022 National Diabetes Statistics Report, more than 37.3 million Americans (or 11.3% of the US population) have diabetes, with roughly 28.7 million diagnosed and 8.5 million undiagnosed. The number of individuals diagnosed with diabetes has more than quadrupled over the previous 20 years, resulting in a significant and rising need for insulin syringes.

Ageing Population Growth: According to the United States Census Bureau, the number of Americans aged 65 and over is expected to reach 77 million in 2034. This age change is especially relevant for the insulin syringe industry, as type 2 diabetes is more common in older persons.

The National Diabetes Audit (NDA) and the National Paediatric Diabetes Audit (NPDA) provide a comprehensive view of diabetes care in England and Wales. They measure the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. This is the second Young People with Type 2 Diabetes report (1). It aims to document the number of people with type 2 diabetes up to the age of 40 years, their patient characteristics and the diabetes care they receive. This is important because adverse diabetes and cardiovascular outcomes are more common in people who develop type 2 diabetes at an earlier age and it is thought the numbers of affected individuals are increasing (2,3).

The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded and managed by NHS England, in partnership with Diabetes UK. The NDA provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. The NDA supports improvement in the quality of diabetes care by enabling participating NHS services and organisations to: Assess local practice against NICE guidelines. Compare their care, and care outcomes, with similar services and organisations, identify gaps or shortfalls that are priorities for improvement, identify and share best practice and provide a comprehensive national picture of diabetes care and outcomes in England and Wales. This data release includes the care process and treatment target measurements for the full 2022-23 audit period (1 January 2022 – 31 March 2023); presented for England primary care and specialist services (hospital-based care), each with its own separate data file. Please note, primary care data for Wales is not yet available. Data for Wales will be made available in January 2024. Data from primary care in England was collected throughout the audit period. Data for specialist services in England is submitted throughout the year with the January 2022 to March 2023 cut of this data being taken in June 2023. Data from Wales was received in November 2023 and will be released in January 2024.

The information available from this webpage comes from the National Diabetes Inpatient Safety Audit (NDISA). The NDISA measures the frequency of avoidable diabetic harms. The NDISA audit is part of the National Diabetes Audit (NDA) programme commissioned by the Healthcare Quality Improvement Partnership (HQIP) and managed by NHS England, in collaboration with Diabetes UK. Making clinical audit data transparent In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme (NCAPOP). What information is being made available? NDISA data for 2018-2021 covers the provision of inpatient services in England and Wales and diabetes-specific inpatient harms in England. These data do not list individual patient information nor do they contain any patient identifiable data. Using and interpreting the data Data from NDISA should not be looked at in isolation when assessing standards of care. Accessing the data The data are being made available on the data.gov website. For each NDISA report, a data file will be made available in CSV format. What period does the data cover? The NDISA 2018-2021 report covers: the provision of inpatient services in England and Wales on 1 October 2021; and diabetes-specific inpatient harms in England between May 2018 and October 2021. The report was published on 14 July 2022.

The worksheets include data for all sub-ICB locations and GP practices in England within the May 2022 extraction of NDA data (January to June 2022 data). These data are provisional and have been subject to fewer data quality and validation checks than data included in final NDA publications. Data for Local Health Boards (LHB) in Wales and specialist diabetes services in England are not included in the quarterly publications. Their 2022-23 data (for the full audit period January 2022 to March 2023) will be extracted as part of the final NDA 2022-23 collection and reported in the NDA 2022-23 full audit period data release and state of the nation report, scheduled for late 2023 and summer 2024 respectively. Disclosure control has been applied to mitigate the risk of patient identification. Zeros are reported, and all numbers are rounded to the nearest 5, unless the number is 1 to 7, in which case it is rounded to ‘5’. This allows for more granular data to be made available, and also for data for all GP practices to be made available.

Discover the booming China diabetes treatment market: A comprehensive analysis reveals a $12.34 billion market in 2025, projected to grow at a CAGR of 2.70% until 2033, driven by rising prevalence and new drug classes. Explore key players, market segments (insulin, oral anti-diabetics, injectables), and future trends. Recent developments include: April 2023: National Healthcare Security Administration announced that China's diabetes patients can now access high-quality and more affordable insulin products, as the country's drug bulk-buying program for insulin products led to an average price cut of 48%. The centralized procurement is estimated to save CNY 9 billion (about USD 1.31 billion) in diabetes-related health expenditures yearly., October 2022: Hua Medicine announced that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator developed by the Company, was officially approved by the National Medical Products Administration (NMPA) of China. It is to be used as monotherapy for drug naïve Type 2 diabetes patients or combined with metformin in metformin-tolerated Type 2 diabetes to control blood glucose levels.. Notable trends are: The oral anti-diabetic drugs segment holds the highest market share in the China Diabetes Care Drugs Market in the current year.

The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded by NHS England. The NDA is managed by NHS Digital in partnership with Diabetes UK. The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards. The NDA supports improvement in the quality of diabetes care by enabling participating NHS services and organisations to: Assess local practice against NICE guidelines. Compare their care, and care outcomes, with similar services and organisations. Identify gaps or shortfalls that are priorities for improvement. Identify and share best practice and provide a comprehensive national picture of diabetes care and outcomes in England and Wales. This data release includes the care process and treatment target measurements for 2020-21 (1st January 2020 – 31st March 2021). Data were collected during May and June 2021. The national report, scheduled for 2022, will contain commentary on the audit findings and recommendations. We will communicate to users when the publication date for this report has been finalised. Note: An issue was identified with the Wales data release whereby structured education offered data was underreported. This has now been corrected in the version of the file available on this webpage.

The excel file contains unit, regional and national level data obtained from the National Paediatric Diabetes Audit 2022-2023. Specifically, it includes information on patient characteristics, completion of health checks and outcomes achieved (as recommended by the National Institute for Clinical Excellence) for infants, children and young people with type 1 diabetes, under the age of 25, who attended paediatric diabetes units in England and Wales between 1 April 2022 and the 31 March 2023. Data are included for the seven key health checks: • Glycated Haemoglobin A1c (HbA1c) • Body Mass Index (BMI) • Thyroid • Blood pressure • Urinary albumin • Foot examination • Eye screening. Data on other health checks include: • Psychological assessment • Offering of immunisation against influenza • Advice about managing diabetes (‘sick-day rules’) • Using (or trained to use) blood ketone testing strips and a meter • Cholesterol • Additional dietetic support Data are included for health checks at diagnosis • Screening for autoimmune disease (coeliac and thyroid disease) • Provision of Level 3 carbohydrate-counting education Data on outcomes of care include: • HbA1c target measurements • Small vessel (microvascular) disease • Large vessel (macrovascular) disease • Autoimmune disease (coeliac and thyroid disease) The data were first published in 2024 alongside the National Paediatric Diabetes Audit Report 2022-2023 Data suppressed due to small numbers (

The worksheets include data for all integrated care boards (ICBs) and GP practices in England within the December 2023 extraction of the National Diabetes Audit (NDA) data (January to September 2023 data). These data undergo further validation processes at the end of each audit year when data from specialist services are added in, at which point the data are considered to comprise the full annual dataset to be used in the annual NDA publications. This release includes data for Detained Estates for the first time (121 eligible organisations). Detained Estates include prisons, young offender institutes, children's homes and immigration removal centres. Data for local health boards (LHBs) in Wales and specialist diabetes services in England are not included in the quarterly publications. The 2022-23 data (for the full audit period January 2022 to March 2023) is reported separately and a corresponding state of the nation report is scheduled for summer 2024. Disclosure control has been applied to mitigate the risk of patient identification. Zeros are reported, and all numbers are rounded to the nearest 5, unless the number is 1 to 7, in which case it is rounded to ‘5’. This allows for more granular data to be made available, and also for data for all GP practices to be made available. Percentages where the denominator is less than or equal to 20 are not reliable and have therefore not been calculated in this release.

The Harmonised Data in Five National Longitudinal Cohort Studies project, supported by the Economic and Social Research Council (ESRC), brings together data from five British cohort studies: the 1946 National Survey of Health and Development (NSHD), the 1958 National Child Development Survey (NCDS), the 1970 British Cohort Study (BCS70), Next Steps (formerly the Longitudinal Study of Young People in England), and the Millennium Cohort Study (MCS). NCDS, BCS70, Next Steps, and MCS receive core funding from the ESRC and are hosted by the Centre for Longitudinal Studies at UCL. NSHD is funded by the Medical Research Council (MRC) and is hosted by the Unit for Lifelong Health and Ageing at UCL.

The Diabetes Harmonisation project aimed to document all self-reported measures related to diabetes in these five British cohort studies and produce harmonised indicators of self-reported diabetes through retrospective harmonisation. This harmonisation serves two primary purposes: improving the measurement of diabetes (as an outcome, predictor, or control variable) within cohort analyses, and facilitating cross-cohort research on diabetes using these rich datasets.

Separate longitudinal datasets were created for each cohort, focusing on self-reported data with some information derived from doctors' reports and medical records. Biomarkers and linked health data were not included. Focus was given to measures that were administered to entire cohorts only and on the diabetes status of cohort members themselves (not their parents or children).

SN 9421 includes harmonised diabetes data for the MRC National Survey of Health and Development only. Harmonised diabetes data for NCDS, BCS70, Next Steps and MCS are available under Safeguarded data access from SN 9416.

The National Pregnancy in Diabetes Audit (NPID) is a workstream of the National Diabetes Audit (NDA) and is managed by NHS England (formally NHS Digital) under an agreement with the Healthcare Quality Improvement Partnership (HQIP). The NDA is delivered by NHS England, in partnership with Diabetes UK. The audit has been running since 2014. This is the seventh National Pregnancy in Diabetes (NPID) audit report on pregnancy outcomes in women with pre-existing diabetes in pregnancy in England and Wales. This State of the Nation overview details the findings and recommendations relating to the demographics, treatment and pregnancy outcomes of mothers with type 1 and early-onset type 2 diabetes. It covers the period 01 January 2021 to 31 December 2022.

The National Pregnancy in Diabetes Audit (NPID) is a workstream of the National Diabetes Audit (NDA). It aims to support clinical teams to deliver better care and outcomes for women with diabetes who become pregnant and has been running since 2014. The dashboard presents service level data and is intended to support local, regional and national quality improvement. The latest version of the dashboard reports on data collected for pregnancies that ended between 1 January 2022 and 31 December 2024 and includes data on continuous glucose monitoring (CGM). Data are submitted by antenatal services in England and Wales.

The NHS Diabetes Prevention Programme (DPP) is a joint commitment from NHS England, Office for Health Improvement and Disparities (OHID, formerly Public Health England) and Diabetes UK to deliver, at scale, evidence based behavioural interventions that can prevent or delay the onset of type 2 diabetes in adults who have been identified as having non-diabetic hyperglycaemia (NDH). This is the annual report for 2021-22 on people with non-diabetic hyperglycaemia and people seen by the DPP. This detailed report accompanies the 'State of the Nation' summary report for 2021-22. The report primarily uses data from English GP practice systems for 2021-22; and also includes data generated by providers of the DPP relating to referrals up to March 2022. The GP data is only for people diagnosed and recorded with NDH.

The NHS Diabetes Prevention Programme (DPP) is a joint commitment from NHS England and Diabetes UK to deliver, at scale, evidence based behavioural interventions that can prevent or delay the onset of Type 2 diabetes in adults who have been identified as having non-diabetic hyperglycaemia (NDH). This report presents the national audit findings, summarising registration and demographic information on people registered in GP Practices in England who have non-diabetic hyperglycaemia. Also presented are the numbers of people recorded in GP practices as having been offered DPP behavioural change courses up to the end of March 2023, and the numbers that have declined, or not declined, to attend these courses. Non-diabetic hyperglycaemia involves blood glucose levels that are above normal levels, but not in the diabetic range. The report is for England only. The data has not been through the full data assurance process that is carried out on the annual data, but is a provisional reflection of progress over this period.

The percentage of people with diabetes who have received nine care processes. As of March 2018, please refer to the data tables published by NHS Digital in the National Diabetes Audit (NDA) publications. These publications are released on an annual basis. A link to the National Diabetes Audit homepage and the most recent annual publication is available via the resource link below. Prior to March 2018, within the indicator data files data for type 1 and type 2 diabetes were presented as a combined figure. Following guidance from the National Diabetes Audit (NDA) Advisory Group suggesting type 1 and type 2 diabetes are fundamentally different diseases, the data presented within the NDA publications is presented for type 1 and type 2 diabetes separately. Within a publication navigate to the Resources section at the bottom of the page and select the Excel file titled ‘National Diabetes Audit 2017-18 Short Report, Interactive Report England’. The tabs of interest for the indicator are as follows: Participation – Participation rates for the CCGs Type 1 CP_TT columns BY-CA – Type 1 diabetes indicator data Type 2 and other CP_TT columns BY-CA – Type 2 diabetes indicator data Legacy unique identifier: P01830